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Five enzyme-linked immunosorbent assays developed to detect antibodies to different Burkholderia pseudo-
mallei antigen preparations were evaluated as diagnostic tests for melioidosis in northeast Thailand. The
highest diagnostic indices were observed for an affinity-purified antigen (sensitivity, 82%; specificity, 72%) and
crude B. pseudomallei antigen (sensitivity, 81%; specificity, 70%), an improvement over the indirect hemagglu-
tination assay (sensitivity, 73%; specificity, 64%).
Burkholderia pseudomallei is the causative agent of melioido-
sis, a disease of public health importance in Southeast Asia and
northern Australia (4, 22). This bacterium is present in the
environment in areas of endemicity where natural infection is
acquired following inoculation or inhalation (4, 22). Clinical
manifestations of melioidosis are broad ranging and are often
difficult to differentiate from other infections, but accurate
diagnosis is important, since melioidosis requires prolonged
antimicrobial therapy of 20 weeks to achieve cure (4, 24).
Although culture of B. pseudomallei represents the diagnostic
gold standard, rural hospitals in Asia may lack culture facilities
but often have access to serological tests. The most widely used
serological test for the diagnosis of melioidosis is the indirect
hemagglutination assay (IHA) (5, 6, 8, 13, 14). However, this
assay has a low diagnostic accuracy in settings of endemicity,
since rates of seropositivity in the general population are high
(12, 23); this is most likely the result of repeated environmental
exposure to B. pseudomallei or possibly the highly related but
nonvirulent Burkholderia thailandensis. Many previous at-
tempts have been made to improve the accuracy of serology
tests for melioidosis using a range of antigen preparations in an
enzyme-linked immunosorbent assay (ELISA) format (7, 10,
15, 17–19, 20). Some studies have suggested that immunoglob-
ulin G (IgG) assays using whole-cell antigens are more specific
for acute infection (7, 10, 20). Studies using purified antigens
such as lipopolysaccharide (LPS) or exopolysaccharide (EPS)
have also been conducted (10, 15, 17, 18), but these have
generally been evaluated in small sample collections and have
demonstrated varying sensitivities and specificities. The aim of
this study was to compare the diagnostic utilities of ELISAs
using crude and purified B. pseudomallei antigens (LPS, EPS,
and affinity-purified antigen) in a single highly defined popu-
lation of patients with suspected melioidosis in northeast Thai-
land. We also assessed the relationship between antibody re-
sponses to different B. pseudomallei antigen preparations and
the extent of cross-reactivity between B. pseudomallei and B.
thailandensis antigens.
Serum samples were obtained upon admission from un-
selected adult patients presenting with suspected melioidosis
to Sappasithiprasong Hospital, Ubon Ratchathani, northeast
Thailand, between June and October 2004. Patients with sus-
pected melioidosis were identified by active ward surveillance,
and multiple samples were taken for culture. Isolation of B.
pseudomallei from any sample was considered diagnostic. Of
the 322 patients clinically suspected to have melioidosis, 120
had culture-confirmed infection, and the remainder (n 
202) acted as controls. Ethical approval was obtained from
the Ethics Subcommittee, Faculty of Tropical Medicine,
Mahidol University.
Crude antigens were prepared from aqueous extracts of B.
pseudomallei K96243 and B. thailandensis E32 (isolated from
soil in northeast Thailand) grown on Trypticase soy agar at
37°C for 2 days. Bacteria from 10 Trypticase soy agar plates
were harvested into 30 ml of phosphate-buffered saline (PBS),
pH 7.2, and heat killed at 80°C for 1 h. Bacterial LPS and EPS
were extracted using the hot-phenol chloroform method, as pre-
viously described (11). EPS and LPS were extracted simulta-
neously from B. pseudomallei K96243. LPS alone was extracted
from the EPS-defective mutant B. pseudomallei SR1015 (16), and
EPS alone was extracted from the LPS-defective mutant B.
pseudomallei SRM 117 (both mutants kindly provided by
Donald Woods, University of Calgary, Canada) (9). The
monoclonal antibody 4B11 to B. pseudomallei EPS (3) was
used to prepare affinity-purified antigen, as previously de-
scribed (17). All suspensions were sterility tested, quantitated
on the basis of carbohydrate content using the orcinol-sulfuric
acid method (21), and stored at 20°C prior to use.
Pilot studies were performed to define the optimal concen-
tration of serum and antigen using pooled positive and pooled
control sera (5 patients with culture-proven melioidosis and 5
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healthy volunteers who were IHA negative, respectively) at a
dilution range of 1:1,000 to 1:16,000. The six antigens were
diluted in 0.05 M carbonate buffer, pH 9.6, to achieve a range
of concentrations. Each antigen was added in duplicate to a
96-well ELISA plate in a fixed volume of 100 l per well and
maintained overnight at 4°C. Plates were then washed three
times with normal saline containing 0.05% Tween 20 and
blocked at 37°C for 2 h with 200 l of 5% skim milk in PBS.
After a further washing step, 100 l of sera diluted in PBS with
1% bovine serum albumin and 0.05% Tween 20 were added to
wells in duplicate and incubated at room temperature for
1 h. After washing of the plates as described above, a 1:2,000
dilution of horseradish peroxidase-conjugated rabbit anti-
human IgG (Dako, Copenhagen, Denmark) was added, and
the mixture was incubated at room temperature for 1 h.
After the plates were washed six times, the enzymatic activ-
ity was determined using a substrate solution containing
O-phenylenediamine (0.67 mg/ml) and hydrogen peroxide
(1.5%), using incubation at room temperature for 30 min.
The reaction was stopped with 50 l of H2SO4, and the
absorbance value (optical density [OD]) was determined at
a wavelength 492 nm. The optimal concentrations for each
antigen were as follows: LPS, 100 ng/ml; EPS, 500 ng/ml;
EPS plus LPS, 100 ng/ml; 4B11 affinity-purified antigen, 30
ng/ml; crude B. pseudomallei, 250 ng/ml; and crude B. thai-
landensis, 250 ng/ml. The optimal concentration of sera was
1:4,000 for all ELISAs. The 322 individual sera were tested
in duplicate using these optimized values. The IHA was
performed as previously described (1), using pooled anti-
gens from clinical isolates 199a and 207a of B. pseudomallei
cultured from patients with melioidosis in northeast Thailand.
The diagnostic cutoff used was 1:160 (12). Serum samples
were tested in random order to ensure mixing between cases
and controls.
Diagnostic accuracy was calculated for each assay using cul-
ture-confirmed cases of melioidosis as the gold standard.
ELISA values used were the means of results from duplicate
wells minus background (reagent blank). Diagnostic ELISA
cutoffs were chosen for each B. pseudomallei assay based on the
highest proportion of patients correctly classified. Sensitivity,
specificity, negative predictive values (NPV), positive predic-
tive values (PPV), positive and negative likelihood ratios
(LR and LR, respectively), area under the receiver oper-
ator characteristic curves (AUROCC), and correlation coeffi-
cients were calculated using Stata 8.0 (College Station, Texas).
Log-transformed IHA titers were used for analysis of correla-
tion with ELISAs.
Table 1 shows the diagnostic accuracy indices for the five B.
pseudomallei ELISAs and IHA using sera from 322 patients
with suspected melioidosis. The highest indices were observed
for the affinity-purified antigen and crude B. pseudomallei an-
tigen ELISAs. AUROCC were statistically equivalent for the
affinity-purified antigen, crude B. pseudomallei antigen, EPS
plus LPS, and LPS ELISA (P  0.76).
To further evaluate the five ELISAs, we examined seropos-
itivity in individuals resident in areas of high and low melioi-
dosis endemicity (northeast and southern Thailand, respec-
tively). Serum was obtained from 300 children resident in
northeast Thailand who presented to Sappasithiprasong Hos-
pital between 2004 and 2005 for reasons other than melioidosis
(age range, 1 to 14 years; median, 7.5 years, interquartile
range, 4 to 11 years) and 113 adults without melioidosis pre-
senting to Takuapa General Hospital, Phangnga, southern
Thailand, between 2004 and 2005 (age range, 19 to 91 years;
median, 37 years; interquartile range, 29 to 47 years). Figure 1
shows the proportion positive for each of the assays using the
diagnostic ELISA cutoffs given in Table 1 and an IHA cutoff of
1:160. The highest positivity rates were observed for EPS and
IHA; this is consistent with the lower diagnostic indices for
these assays in the patient population with suspected melioi-
dosis. These data provide further evidence for the presence
and extent of seropositivity to B. pseudomallei in Thailand, a
phenomenon that has a major effect on serodiagnostic test
specificity.
Serum from the 322 patients with suspected melioidosis was
tested using the crude B. thailandensis antigen ELISA. Diag-
nostic indices (for the diagnosis of melioidosis) were calculated
for the B. thailandensis antigen ELISA using a cutoff of 0.441
FIG. 1. Proportion of healthy individuals with an antibody titer
above the diagnostic cutoff for the IHA and five B. pseudomallei
ELISAs using different antigen (Ag) preparations. Error bars repre-
sent 95% CIs.
TABLE 1. Test characteristics of five B. pseudomallei ELISA and IHA in 322 patients with suspected melioidosisa
Assay Cutoff Sensitivity (%) Specificity (%) PPV (%) NPV (%) % Correctlyclassified LR LR AUROCC
Affinity-purified antigen 0.386 82 (74, 88) 72 (66, 78) 64 (56, 71) 87 (81, 92) 76 3.0 0.25 0.80 (0.75, 0.85)
Crude B. pseudomallei 0.482 81 (73, 87) 70 (63, 77) 62 (54, 69) 86 (80, 91) 74 2.7 0.27 0.80 (0.74, 0.84)
EPS  LPS 0.434 77 (68, 84) 74 (75, 86) 64 (55, 72) 84 (78, 89) 75 3.0 0.31 0.79 (0.74, 0.84)
LPS 0.683 66 (57, 74) 81 (75, 86) 67 (58, 75) 80 (74, 85) 75 3.4 0.42 0.80 (0.74, 0.85)
EPS 0.133 64 (55, 73) 74 (68, 80) 60 (51, 68) 78 (71, 83) 71 2.5 0.48 0.72 (66, 77)
IHA 1:160 73 (64, 80) 64 (57, 71) 55 (47, 63) 80 (73, 86) 67 2.0 0.43 0.75 (0.69, 0.80)
a Values in parentheses represent 95% CIs. Sensitivity, specificity, LR, and LR were calculated at the cutoff OD.
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and were as follows (95% confidence intervals [CIs] are indi-
cated in parentheses): sensitivity, 78% (69 to 85%); specificity,
74% (67 to 80%); PPV, 64% (55 to 71%); NPV, 85% (78 to
90%); correct classification, 75%; LR, 3.0; LR, 0.31;
AUROCC, 0.80 (0.75 to 0.85).
The relationship between antibody responses to different
antigen preparations was examined for the 322 sera from pa-
tients with suspected melioidosis. Table 2 shows the correla-
tion between data for the five B. pseudomallei ELISAs, the B.
thailandensis ELISA, and the IHA. There was high correlation
between crude B. pseudomallei antigen, affinity-purified anti-
gen, and both EPS plus LPS and LPS, but a lower correlation
was observed between crude B. pseudomallei antigen and EPS.
There was a high correlation between affinity-purified antigen
and both EPS plus LPS and LPS alone but a lower correlation
between affinity-purified antigen and EPS alone. This suggests
that the affinity-purified antigen, which was prepared using a
monoclonal antibody to EPS, is likely to be contaminated with
LPS antigen. The IHA correlated poorly with all five ELISAs,
suggesting that alternative bacterial antigens are presented by
the IHA. The B. thailandensis ELISA correlated most closely
with B. pseudomallei ELISAs containing LPS; this is consistent
with previous reports of antigenic similarity between LPS of
the two species (2).
We conclude that the IgG B. pseudomallei ELISA repre-
sents an improvement over IHA. The affinity-purified anti-
gen and crude B. pseudomallei antigen ELISA had the
greater diagnostic performance; the crude antigen ELISA
has the added advantage that antigen is simple to prepare.
However, the goal remains to improve the accuracy of se-
rological tests for the diagnosis of melioidosis. Devising an
assay that has a clinically useful degree of predictive accu-
racy in areas of high endemicity where antibody levels are
high in the healthy population represents a major challenge.
The utility of alternative purified bacterial targets and the
simultaneous use of multiple targets using immunoarray
technology require investigation.
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